307 related articles for article (PubMed ID: 26369978)
1. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.
Sastry S; Clarke LG; Alrowais H; Querry AM; Shutt KA; Doi Y
Antimicrob Agents Chemother; 2015 Dec; 59(12):7355-61. PubMed ID: 26369978
[TBL] [Abstract][Full Text] [Related]
2. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
[TBL] [Abstract][Full Text] [Related]
3. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
4. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
[TBL] [Abstract][Full Text] [Related]
6. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.
Matthews PC; Barrett LK; Warren S; Stoesser N; Snelling M; Scarborough M; Jones N
BMC Infect Dis; 2016 Oct; 16(1):556. PubMed ID: 27729016
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
[TBL] [Abstract][Full Text] [Related]
8. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.
Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S
Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097
[TBL] [Abstract][Full Text] [Related]
9. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
[TBL] [Abstract][Full Text] [Related]
10. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
Araj GF; Jaber FA
J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
[TBL] [Abstract][Full Text] [Related]
12. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
Deemer K; Grey J; Fronczek C; Marr K
Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
15. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
[TBL] [Abstract][Full Text] [Related]
16. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
[TBL] [Abstract][Full Text] [Related]
17. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.
Wu TH; Huang FL; Fu LS; Chou CM; Chien YL; Huang CM; Lin CF; Chen PY
J Microbiol Immunol Infect; 2016 Oct; 49(5):717-722. PubMed ID: 25442872
[TBL] [Abstract][Full Text] [Related]
18. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
[TBL] [Abstract][Full Text] [Related]
19. Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.
Martín-Gutiérrez G; Docobo-Pérez F; Rodriguez-Beltrán J; Rodríguez-Martínez JM; Aznar J; Pascual A; Blázquez J
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038268
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
